United Kingdom (UK)
Recombinant monoclonal antibody to ACE2. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma h166D4 .
UniProt Accession Number of Target Protein: Q9BYF1
Alternative Name(s) of Target: Angiotensin-converting enzyme 2; Angiotensin-converting enzyme homolog; ACEH; Angiotensin-converting enzyme-related carboxypeptidase; ACE-related carboxypeptidase; Metalloprotease MPROT15; 166D4
Immunogen: The original antibody was generated by immunizing BALB/c mice with human ACE2 protein emulsified with complete Freund's adjuvant. The humanized version of the antibody was generated by grafting CDRs onto human framework regions.
Specificity: This antibody binds the extracellular domain of the human ACE2 protein. Angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase enzyme which catalyzes the cleavage of angiotensin I to angiotensin 1-9 and angiotensin II into the vasodilator angiotensin 1-7. This enzyme is a transmembrane protein found on the surface of arteries, heart, kidneys, testis and epithelia of the lung and small intestine. The protein acts as a receptor for spike protein of human coronaviruses SARS-CoV and SARS-CoV-2/2019-nCoV (COVID-19), as well as human coronavirus NL63/HCoV-NL63 and plays a role in virus entry into target cells. Some strategies to treat COVID-19 include blockade of ACE2 receptor and delivery of excess soluble form of ACE2.
Application Notes: The binding characterization of this antibody was done using ELISA. The antibody was reported to bind human ACE2 with a binding affinity of 6.57×10^(-9) M. This antibody can completely block the binding of SARS-CoV-2 RBD to hACE2 and thereby inhibit the infection in host. This antibody can also inhibit the infection of Vero E6 cells with SARS-CoV-2 live virus with high activity, and its IC 50 was 0.22 μg/mL (CN113698487).
Antibody first published in: PMID: